サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1539341

ガンマナイフ市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2032年

Gamma Knife Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032
出版日: | 発行: Persistence Market Research | ページ情報: 英文 102 Pages | 納期: 2～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.16円
ガンマナイフ市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2032年
出版日: 2024年08月20日
発行: Persistence Market Research
ページ情報: 英文 102 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Researchはこのほど、世界のガンマナイフ市場に関する詳細な調査レポートを発行し、促進要因・動向・機会・課題などの市場力学に関する詳細な洞察を提供しました。当レポートは、特に非侵襲的な神経外科治療に焦点を当てたヘルスケアおよび医療機器分野の利害関係者向けに、市場構造と将来展望の包括的な理解を提供することを目的としています。

主要な洞察

  • 世界市場収益（2022年）：2億410万米ドル
  • 推定市場金額（2033年）：3億1,140万米ドル
  • 世界市場成長率（CAGR 2022年～2033年）：4.8%

ガンマナイフの世界市場：調査範囲

ガンマナイフ市場は、主に脳腫瘍、血管奇形、その他の神経疾患の治療に使用される非侵襲的手術ツールであるガンマナイフマシンの生産、流通、使用に焦点を当てています。この市場には、周囲の健康な組織への影響を最小限に抑えながら複雑な脳疾患の治療を可能にする精密放射線手術を通じて、患者の予後を改善することを目的とした幅広い製品とサービスが含まれます。

市場成長の促進要因：

脳腫瘍の有病率の上昇と様々な併用治療法のイントロダクション

脳腫瘍の発生率の上昇と治療法の進歩が、ガンマナイフ市場の成長を促進しています。米国がん協会によると、脳腫瘍はがんの中で8番目に多く、40歳以上のがん死亡原因の第3位です。世界人口の高齢化と拡大に伴い、ガンマナイフ放射線手術を含む効果的な脳腫瘍治療に対する需要は増加すると予想されます。

ガンマナイフ放射線手術は、周囲の健康な脳組織を温存する高度に的を絞った治療法であり、特に多発性脳転移のある患者に適しています。ガンマナイフ放射線手術と生物学的薬剤や免疫学的薬剤の併用もまた、人気を集めています。例えば、Elektaのメラノーマ脳転移に対する併用療法は、免疫療法とガンマナイフ放射線手術を組み合わせたもので、腫瘍制御と患者生存率の改善を示しており、併用治療が市場成長を促進する可能性を強調しています。

規制当局の承認と新製品の発売

ガンマナイフ市場は、規制当局の承認と革新的な製品の採用によってさらに支えられています。例えば、Elektaは2022年5月にIconを発表しました。このガンマナイフシステムは、フレームレスでマスクベースの放射線手術を提供することで、この分野に革命をもたらしました。このシステムはオーストラリアのような地域で特に大きな反響を呼び、神経疾患治療のための脳SRS能力を拡大し、市場成長を後押ししています。

市場の課題：

ガンマナイフ放射線治療装置の高コストと患者の意識の低さ

ガンマナイフ市場が直面する重要な課題の1つは、ガンマナイフ装置の高コストとそれに伴う投資およびメンテナンス費用です。ガンマナイフ装置の初期費用は他の放射線装置よりかなり高く、新興国での導入が制限されています。例えば、インドのガンマナイフ手術は6,500米ドルからですが、欧米諸国では4万米ドルから7万米ドルです。さらに、ガンマナイフ装置に使用されるコバルト60の放射線源は100万米ドルから200万米ドルで、5年ごとに交換が必要なため、全体的な出費につながります。

また、南北アメリカと欧州以外ではガンマナイフ装置の入手可能性が限られており、装置を操作できる熟練した専門家が不足していることも、市場の成長を妨げています。さらに、ガンマナイフ治療に対する一般的な認知度は依然として低く、多くの患者がその利点を知らなかったり、治療法について誤解を抱いたりしています。このような認識や理解の不足は、特に先進ヘルスケア技術へのアクセスが限られている地域において、市場の成長を鈍らせることが予想されます。

本レポートで扱う主要な質問

  • 世界のガンマナイフ市場の成長を促進する主要な要因は何か？
  • ガンマナイフ治療の導入を主導している消費者層は？
  • 放射線手術技術の進歩は競合情勢にどのような影響を与えているか？
  • ガンマナイフの世界市場における主要企業はどこで、市場ポジションを維持するためにどのような戦略を取っているのか？
  • 世界のガンマナイフ市場における新たな動向と将来性は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲 / 分類
  • 市場の定義 / 範囲 / 制限
  • 包含事項・除外事項

第3章 主要な市場動向

  • 市場に影響を与える主要な動向
  • 製品イノベーション / 開発動向

第4章 主要な成功要因

  • 製品の採用 / 使用状況分析
  • 製品のUSP / 特徴
  • インストールベースシナリオ
  • 技術評価
  • 規制状況
  • PESTLE分析
  • ポーター分析
  • バリューチェーン分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因 - 関連性と影響
  • ダイナミクス

第6章 COVID-19危機 - 影響評価

  • COVID-19と影響分析
    • 疾患別
    • 治療対象臓器別
    • 地域別
  • 2024年の市場シナリオ

第7章 世界市場の需要（金額または規模、百万米ドル）分析

  • 過去の市場金額（百万米ドル）分析、2019年～2023年
  • 現在および将来の市場金額（百万米ドル）予測、2024年～2032年
    • 前年比成長動向分析
    • 絶対額の機会分析

第8章 世界市場分析：疾患別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模（百万米ドル）の分析：疾患別、2019年～2023年
  • 現在および将来の市場規模（百万米ドル）の分析と予測：疾患別、2024年～2032年
    • 脳転移
    • がん
    • 動静脈奇形（AVM）
    • 三叉神経痛
    • その他
  • 市場の魅力分析：疾患別

第9章 世界市場分析：治療対象臓器別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模（百万米ドル）の分析：治療対象臓器別、2019年～2023年
  • 現在および将来の市場規模（百万米ドル）分析と予測：治療対象臓器別、2024年～2032年
    • 頭
    • 首
    • その他
  • 市場の魅力分析：治療対象臓器別

第10章 世界市場分析：地域別

  • イントロダクション
  • 過去の市場規模（百万米ドル）の分析：地域別、2019～2023年
  • 現在および将来の市場規模（百万米ドル）の分析と予測：地域別、2024年～2032年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 南アジア
    • 東アジア
    • オセアニア
    • 中東・アフリカ（MEA）
  • 市場の魅力分析：地域別

第11章 北米市場分析

第12章 ラテンアメリカ市場分析

第13章 欧州市場分析

第14章 南アジア市場分析

第15章 東アジア市場分析

第16章 オセアニア市場分析

第17章 中東・アフリカ市場分析

第18章 市場構造分析

  • 市場分析：企業階層別
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第19章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の詳細情報
    • Elekta AB
    • Varian Medical Systems
    • Huiheng Medical, Inc.
    • MASEP Medical Science Technology Development（Shenzhen）Co., Ltd.
    • Akesis Inc.
    • Cyber Medical Corporation Limited.
    • Masep Infini Global, Inc.
    • Nordion, Inc.
    • Hokai
    • ET Medical Group
    • American Shared Hospital Services

第20章 使用される前提条件と頭字語

第21章 調査手法

目次
Product Code: PMRREP3742

Persistence Market Research has recently published an in-depth report on the global gamma knife market, offering detailed insights into market dynamics, including drivers, trends, opportunities, and challenges. This report aims to provide a comprehensive understanding of the market structure and future outlook, particularly for stakeholders in the healthcare and medical device sectors focused on non-invasive neurosurgical treatments.

Key Insights:

  • Global Market Revenue (2022): US$ 204.1 Million
  • Estimated Market Value (2033): US$ 311.4 Million
  • Global Market Growth Rate (CAGR 2022-2033): 4.8%

Global Gamma Knife Market - Report Scope:

The gamma knife market focuses on the production, distribution, and use of gamma knife machines, a non-invasive surgical tool primarily used for treating brain tumors, vascular malformations, and other neurological disorders. This market encompasses a range of products and services aimed at improving patient outcomes through precision radiosurgery, which allows for the treatment of complex brain conditions with minimal impact on surrounding healthy tissues.

Market Growth Drivers:

Rising Prevalence of Brain Tumors Coupled with Introduction of Various Combination Treatment Therapies

The rising incidence of brain tumors, coupled with advancements in treatment modalities, is driving the growth of the gamma knife market. According to the American Cancer Society, brain tumors are the eighth most prevalent type of cancer and the third leading cause of cancer deaths in people aged 40 and older. As the global population ages and expands, the demand for effective brain tumor treatments, including gamma knife radiosurgery, is expected to increase.

Gamma knife radiosurgery offers a highly targeted treatment option that spares surrounding healthy brain tissue, making it particularly suitable for patients with multiple brain metastases. The combination of gamma knife radiosurgery with biological and immunological agents is also gaining traction. For example, Elekta's combination therapy for melanoma brain metastases, which pairs immunotherapy with gamma knife radiosurgery, has shown improved tumor control and patient survival, highlighting the potential for combination treatments to drive market growth.

Regulatory Approvals and New Product Launches

The gamma knife market is further supported by regulatory approvals and the introduction of innovative products. For instance, Elekta introduced the Icon in May 2022, a gamma knife system that revolutionized the field by offering frameless, mask-based radiosurgery. This system has been particularly impactful in regions like Australia, where it has expanded the brain SRS capacity for treating neurological diseases, boosting market growth.

Market Challenges:

High Cost of Gamma Knife Radiotherapy Machines Coupled with Low Awareness of Patients

One of the significant challenges facing the gamma knife market is the high cost of gamma knife machines and the associated investment and maintenance expenses. The initial cost of gamma knife machines is considerably higher than other radiation equipment, which limits adoption in emerging economies. For instance, gamma knife surgery in India starts at USD 6,500, while in Western countries, the price ranges from USD 40,000 to USD 70,000. Additionally, the cobalt-60 radiation source used in gamma knife machines costs between USD 1 million to USD 2 million and requires replacement every five years, contributing to the overall expense.

The market's growth is also hindered by the limited availability of gamma knife machines outside of the Americas and Europe, as well as a shortage of skilled professionals capable of operating the equipment. Furthermore, general awareness of gamma knife treatment remains low, with many patients either unaware of the benefits or harboring misconceptions about the procedure. This lack of awareness and understanding is expected to slow down the market's growth, particularly in regions with limited access to advanced healthcare technologies.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the global gamma knife market?
  • Which consumer segments are leading the adoption of gamma knife treatments?
  • How are advancements in radiosurgery technology influencing the competitive landscape?
  • Who are the key players in the global gamma knife market, and what strategies are they employing to maintain their market position?
  • What are the emerging trends and future prospects in the global gamma knife market?

Competitive Intelligence and Business Strategy:

Leading players in the global gamma knife market, such as Elekta AB, Varian Medical Systems, and Accuray Incorporated, are focusing on product innovation, strategic collaborations, and expanding their geographical presence to maintain a competitive edge. These companies are investing heavily in research and development to create advanced gamma knife systems that offer improved precision and patient outcomes. Collaborations with healthcare providers and government agencies are enhancing market credibility and driving the adoption of these technologies. Additionally, targeted marketing and educational campaigns are crucial for increasing patient awareness and acceptance of gamma knife treatments.

Key Companies Profiled:

  • Elekta AB
  • Varian Medical Systems
  • Huiheng Medical, Inc.
  • MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
  • Akesis Inc.
  • Cyber Medical Corporation Limited.
  • Masep Infini Global, Inc.
  • Nordion, Inc.
  • Hokai
  • ET Medical Group
  • American Shared Hospital Services

Key Segments Covered in Gamma Knife Industry Research

Disease Indication:

  • Brain Metastasis
  • Cancer
  • Arteriovenous Malformation (AVM)
  • Trigeminal Neuralgia
  • Others

Organ Treated:

  • Head
  • Neck
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Technology Roadmap
  • 1.5. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Product Adoption / Usage Analysis
  • 4.2. Product USPs / Features
  • 4.3. Install Base Scenario
  • 4.4. Technology Assessment
  • 4.5. Regulatory Landscape
  • 4.6. PESTLE Analysis
  • 4.7. Porter Analysis
  • 4.8. Value Chain Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure Outlook
    • 5.1.3. Global Radiotherapy Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Prevalence of Obesity
    • 5.2.2. Demand for Non-Invasive Procedures
    • 5.2.3. Growing Burden of Brain Cancer
    • 5.2.4. Increasing Instances of Neurological Disorders
    • 5.2.5. Introduction of Novel Treatment Options
    • 5.2.6. Technological Advancements
    • 5.2.7. Product Adoption Rate
    • 5.2.8. Growing Installed Base
  • 5.3. Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis - Impact Assessment

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Disease Indication
    • 6.1.2. By Organ Treated
    • 6.1.3. By Region
  • 6.2. 2024 Market Scenario

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2023 and Forecast 2024-2032, By Disease Indication

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Disease Indication, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Indication, 2024-2032
    • 8.3.1. Brain Metastasis
    • 8.3.2. Cancer
    • 8.3.3. Arteriovenous Malformation (AVM)
    • 8.3.4. Trigeminal Neuralgia
    • 8.3.5. Others
  • 8.4. Market Attractiveness Analysis By Disease Indication

9. Global Market Analysis 2019-2023 and Forecast 2024-2032, By Organ Treated

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Organ Treated, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Organ Treated, 2024-2032
    • 9.3.1. Head
    • 9.3.2. Neck
    • 9.3.3. Others
  • 9.4. Market Attractiveness Analysis By Organ Treated

10. Global Market Analysis 2019-2023 and Forecast 2024-2032, by Region

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
    • 10.3.1. North America
    • 10.3.2. Latin America
    • 10.3.3. Europe
    • 10.3.4. South Asia
    • 10.3.5. East Asia
    • 10.3.6. Oceania
    • 10.3.7. Middle East and Africa (MEA)
  • 10.4. Market Attractiveness Analysis By Region

11. North America Market Analysis 2019-2023 and Forecast 2024-2032

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 11.3.1. By Country
      • 11.3.1.1. U.S.
      • 11.3.1.2. Canada
    • 11.3.2. By Disease Indication
    • 11.3.3. By Organ Treated
  • 11.4. Market Attractiveness Analysis
    • 11.4.1. By Country
    • 11.4.2. By Disease Indication
    • 11.4.3. By Organ Treated
  • 11.5. Country Level Analysis & Forecast
    • 11.5.1. U.S. Market Analysis
      • 11.5.1.1. Introduction
      • 11.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 11.5.1.2.1. By Disease Indication
        • 11.5.1.2.2. By Organ Treated
    • 11.5.2. Canada Market Analysis
      • 11.5.2.1. Introduction
      • 11.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 11.5.2.2.1. By Disease Indication
        • 11.5.2.2.2. By Organ Treated
  • 11.6. Market Trends
  • 11.7. Key Market Participants - Intensity Mapping
  • 11.8. Drivers and Restraints - Impact Analysis

12. Latin America Market Analysis 2019-2023 and Forecast 2024-2032

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 12.3.1. By Country
      • 12.3.1.1. Brazil
      • 12.3.1.2. Mexico
      • 12.3.1.3. Argentina
      • 12.3.1.4. Rest of Latin America
    • 12.3.2. By Disease Indication
    • 12.3.3. By Organ Treated
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Disease Indication
    • 12.4.3. By Organ Treated
  • 12.5. Country Level Analysis & Forecast
    • 12.5.1. Brazil Market Analysis
      • 12.5.1.1. Introduction
      • 12.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.5.1.2.1. By Disease Indication
        • 12.5.1.2.2. By Organ Treated
    • 12.5.2. Mexico Market Analysis
      • 12.5.2.1. Introduction
      • 12.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.5.2.2.1. By Disease Indication
        • 12.5.2.2.2. By Organ Treated
    • 12.5.3. Argentina Market Analysis
      • 12.5.3.1. Introduction
      • 12.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 12.5.3.2.1. By Disease Indication
        • 12.5.3.2.2. By Organ Treated
  • 12.6. Market Trends
  • 12.7. Key Market Participants - Intensity Mapping
  • 12.8. Drivers and Restraints - Impact Analysis

13. Europe Market Analysis 2019-2023 and Forecast 2024-2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 13.3.1. By Country
      • 13.3.1.1. Germany
      • 13.3.1.2. France
      • 13.3.1.3. Italy
      • 13.3.1.4. U.K.
      • 13.3.1.5. Spain
      • 13.3.1.6. Russia
      • 13.3.1.7. BENELUX
      • 13.3.1.8. Nordic Countries
      • 13.3.1.9. Rest of Europe
    • 13.3.2. By Disease Indication
    • 13.3.3. By Organ Treated
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Disease Indication
    • 13.4.3. By Organ Treated
  • 13.5. Country Level Analysis & Forecast
    • 13.5.1. Germany Market Analysis
      • 13.5.1.1. Introduction
      • 13.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.1.2.1. By Disease Indication
        • 13.5.1.2.2. By Organ Treated
    • 13.5.2. France Market Analysis
      • 13.5.2.1. Introduction
      • 13.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.2.2.1. By Disease Indication
        • 13.5.2.2.2. By Organ Treated
    • 13.5.3. Italy Market Analysis
      • 13.5.3.1. Introduction
      • 13.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.3.2.1. By Disease Indication
        • 13.5.3.2.2. By Organ Treated
    • 13.5.4. U.K. Market Analysis
      • 13.5.4.1. Introduction
      • 13.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.4.2.1. By Disease Indication
        • 13.5.4.2.2. By Organ Treated
    • 13.5.5. Spain Market Analysis
      • 13.5.5.1. Introduction
      • 13.5.5.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.5.2.1. By Disease Indication
        • 13.5.5.2.2. By Organ Treated
    • 13.5.6. Russia Market Analysis
      • 13.5.6.1. Introduction
      • 13.5.6.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.6.2.1. By Disease Indication
        • 13.5.6.2.2. By Organ Treated
    • 13.5.7. Nordic Countries Market Analysis
      • 13.5.7.1. Introduction
      • 13.5.7.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.7.2.1. By Disease Indication
        • 13.5.7.2.2. By Organ Treated
    • 13.5.8. BENELUX Market Analysis
      • 13.5.8.1. Introduction
      • 13.5.8.2. Market Analysis and Forecast by Market Taxonomy
        • 13.5.8.2.1. By Disease Indication
        • 13.5.8.2.2. By Organ Treated
  • 13.6. Market Trends
  • 13.7. Key Market Participants - Intensity Mapping
  • 13.8. Drivers and Restraints - Impact Analysis

14. South Asia Market Analysis 2019-2023 and Forecast 2024-2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 14.3.1. By Country
      • 14.3.1.1. India
      • 14.3.1.2. Thailand
      • 14.3.1.3. Indonesia
      • 14.3.1.4. Malaysia
      • 14.3.1.5. Rest of South Asia
    • 14.3.2. By Disease Indication
    • 14.3.3. By Organ Treated
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Disease Indication
    • 14.4.3. By Organ Treated
  • 14.5. Country Level Analysis & Forecast
    • 14.5.1. India Market Analysis
      • 14.5.1.1. Introduction
      • 14.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.1.2.1. By Disease Indication
        • 14.5.1.2.2. By Organ Treated
    • 14.5.2. Thailand Market Analysis
      • 14.5.2.1. Introduction
      • 14.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.2.2.1. By Disease Indication
        • 14.5.2.2.2. By Organ Treated
    • 14.5.3. Indonesia Market Analysis
      • 14.5.3.1. Introduction
      • 14.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.3.2.1. By Disease Indication
        • 14.5.3.2.2. By Organ Treated
    • 14.5.4. Malaysia Market Analysis
      • 14.5.4.1. Introduction
      • 14.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.4.2.1. By Disease Indication
        • 14.5.4.2.2. By Organ Treated
  • 14.6. Market Trends
  • 14.7. Key Market Participants - Intensity Mapping
  • 14.8. Drivers and Restraints - Impact Analysis

15. East Asia Market Analysis 2019-2023 and Forecast 2024-2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 15.3.1. By Country
      • 15.3.1.1. China
      • 15.3.1.2. Japan
      • 15.3.1.3. South Korea
    • 15.3.2. By Disease Indication
    • 15.3.3. By Organ Treated
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Disease Indication
    • 15.4.3. By Organ Treated
  • 15.5. Country Level Analysis & Forecast
    • 15.5.1. China Market Analysis
      • 15.5.1.1. Introduction
      • 15.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.1.2.1. By Disease Indication
        • 15.5.1.2.2. By Organ Treated
    • 15.5.2. Japan Market Analysis
      • 15.5.2.1. Introduction
      • 15.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.2.2.1. By Disease Indication
        • 15.5.2.2.2. By Organ Treated
    • 15.5.3. South Korea Market Analysis
      • 15.5.3.1. Introduction
      • 15.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.3.2.1. By Disease Indication
        • 15.5.3.2.2. By Organ Treated
  • 15.6. Market Trends
  • 15.7. Key Market Participants - Intensity Mapping
  • 15.8. Drivers and Restraints - Impact Analysis

16. Oceania Market Analysis 2019-2023 and Forecast 2024-2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 16.3.1. By Country
      • 16.3.1.1. Australia
      • 16.3.1.2. New Zealand
    • 16.3.2. By Disease Indication
    • 16.3.3. By Organ Treated
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Disease Indication
    • 16.4.3. By Organ Treated
  • 16.5. Country Level Analysis & Forecast
    • 16.5.1. Australia Market Analysis
      • 16.5.1.1. Introduction
      • 16.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.1.2.1. By Disease Indication
        • 16.5.1.2.2. By Organ Treated
    • 16.5.2. New Zealand Market Analysis
      • 16.5.2.1. Introduction
      • 16.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.2.2.1. By Disease Indication
        • 16.5.2.2.2. By Organ Treated
  • 16.6. Market Trends
  • 16.7. Key Market Participants - Intensity Mapping
  • 16.8. Drivers and Restraints - Impact Analysis

17. Middle East and Africa Market Analysis 2019-2023 and Forecast 2024-2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 17.3.1. By Country
      • 17.3.1.1. GCC Countries
      • 17.3.1.2. Turkiye
      • 17.3.1.3. Northern Africa
      • 17.3.1.4. South Africa
      • 17.3.1.5. Rest of Middle East and Africa
    • 17.3.2. By Disease Indication
    • 17.3.3. By Organ Treated
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Disease Indication
    • 17.4.3. By Organ Treated
  • 17.5. Country Level Analysis & Forecast
    • 17.5.1. GCC Countries Market Analysis
      • 17.5.1.1. Introduction
      • 17.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.1.2.1. By Disease Indication
        • 17.5.1.2.2. By Organ Treated
    • 17.5.2. Turkiye Market Analysis
      • 17.5.2.1. Introduction
      • 17.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.2.2.1. By Disease Indication
        • 17.5.2.2.2. By Organ Treated
    • 17.5.3. Northern Africa Market Analysis
      • 17.5.3.1. Introduction
      • 17.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.3.2.1. By Disease Indication
        • 17.5.3.2.2. By Organ Treated
    • 17.5.4. South Africa Market Analysis
      • 17.5.4.1. Introduction
      • 17.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.4.2.1. By Disease Indication
        • 17.5.4.2.2. By Organ Treated
  • 17.6. Market Trends
  • 17.7. Key Market Participants - Intensity Mapping
  • 17.8. Drivers and Restraints - Impact Analysis

18. Market Structure Analysis

  • 18.1. Market Analysis by Tier of Companies
  • 18.2. Market Share Analysis of Top Players
  • 18.3. Market Presence Analysis

19. Competition Analysis

  • 19.1. Competition Dashboard
  • 19.2. Competition Benchmarking
  • 19.3. Competition Deep Dive
    • 19.3.1. Elekta AB
      • 19.3.1.1. Overview
      • 19.3.1.2. Disease Indication Portfolio
      • 19.3.1.3. Key Financials
      • 19.3.1.4. Sales Footprint
      • 19.3.1.5. SWOT Analysis
      • 19.3.1.6. Strategy Overview
        • 19.3.1.6.1. Marketing Strategy
        • 19.3.1.6.2. Product Strategy
        • 19.3.1.6.3. Channel Strategy
    • 19.3.2. Varian Medical Systems
      • 19.3.2.1. Overview
      • 19.3.2.2. Disease Indication Portfolio
      • 19.3.2.3. Key Financials
      • 19.3.2.4. Sales Footprint
      • 19.3.2.5. SWOT Analysis
      • 19.3.2.6. Strategy Overview
        • 19.3.2.6.1. Marketing Strategy
        • 19.3.2.6.2. Product Strategy
        • 19.3.2.6.3. Channel Strategy
    • 19.3.3. Huiheng Medical, Inc.
      • 19.3.3.1. Overview
      • 19.3.3.2. Disease Indication Portfolio
      • 19.3.3.3. Key Financials
      • 19.3.3.4. Sales Footprint
      • 19.3.3.5. SWOT Analysis
      • 19.3.3.6. Strategy Overview
        • 19.3.3.6.1. Marketing Strategy
        • 19.3.3.6.2. Product Strategy
        • 19.3.3.6.3. Channel Strategy
    • 19.3.4. MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
      • 19.3.4.1. Overview
      • 19.3.4.2. Disease Indication Portfolio
      • 19.3.4.3. Key Financials
      • 19.3.4.4. Sales Footprint
      • 19.3.4.5. SWOT Analysis
      • 19.3.4.6. Strategy Overview
        • 19.3.4.6.1. Marketing Strategy
        • 19.3.4.6.2. Product Strategy
        • 19.3.4.6.3. Channel Strategy
    • 19.3.5. Akesis Inc.
      • 19.3.5.1. Overview
      • 19.3.5.2. Disease Indication Portfolio
      • 19.3.5.3. Key Financials
      • 19.3.5.4. Sales Footprint
      • 19.3.5.5. SWOT Analysis
      • 19.3.5.6. Strategy Overview
        • 19.3.5.6.1. Marketing Strategy
        • 19.3.5.6.2. Product Strategy
        • 19.3.5.6.3. Channel Strategy
    • 19.3.6. Cyber Medical Corporation Limited.
      • 19.3.6.1. Overview
      • 19.3.6.2. Disease Indication Portfolio
      • 19.3.6.3. Key Financials
      • 19.3.6.4. Sales Footprint
      • 19.3.6.5. SWOT Analysis
      • 19.3.6.6. Strategy Overview
        • 19.3.6.6.1. Marketing Strategy
        • 19.3.6.6.2. Product Strategy
        • 19.3.6.6.3. Channel Strategy
    • 19.3.7. Masep Infini Global, Inc.
      • 19.3.7.1. Overview
      • 19.3.7.2. Disease Indication Portfolio
      • 19.3.7.3. Key Financials
      • 19.3.7.4. Sales Footprint
      • 19.3.7.5. SWOT Analysis
      • 19.3.7.6. Strategy Overview
        • 19.3.7.6.1. Marketing Strategy
        • 19.3.7.6.2. Product Strategy
        • 19.3.7.6.3. Channel Strategy
    • 19.3.8. Nordion, Inc.
      • 19.3.8.1. Overview
      • 19.3.8.2. Disease Indication Portfolio
      • 19.3.8.3. Key Financials
      • 19.3.8.4. Sales Footprint
      • 19.3.8.5. SWOT Analysis
      • 19.3.8.6. Strategy Overview
        • 19.3.8.6.1. Marketing Strategy
        • 19.3.8.6.2. Product Strategy
        • 19.3.8.6.3. Channel Strategy
    • 19.3.9. Hokai
      • 19.3.9.1. Overview
      • 19.3.9.2. Disease Indication Portfolio
      • 19.3.9.3. Key Financials
      • 19.3.9.4. Sales Footprint
      • 19.3.9.5. SWOT Analysis
      • 19.3.9.6. Strategy Overview
        • 19.3.9.6.1. Marketing Strategy
        • 19.3.9.6.2. Product Strategy
        • 19.3.9.6.3. Channel Strategy
    • 19.3.10. ET Medical Group
      • 19.3.10.1. Overview
      • 19.3.10.2. Disease Indication Portfolio
      • 19.3.10.3. Key Financials
      • 19.3.10.4. Sales Footprint
      • 19.3.10.5. SWOT Analysis
      • 19.3.10.6. Strategy Overview
        • 19.3.10.6.1. Marketing Strategy
        • 19.3.10.6.2. Product Strategy
        • 19.3.10.6.3. Channel Strategy
    • 19.3.11. American Shared Hospital Services
      • 19.3.11.1. Overview
      • 19.3.11.2. Disease Indication Portfolio
      • 19.3.11.3. Key Financials
      • 19.3.11.4. Sales Footprint
      • 19.3.11.5. SWOT Analysis
      • 19.3.11.6. Strategy Overview
        • 19.3.11.6.1. Marketing Strategy
        • 19.3.11.6.2. Product Strategy
        • 19.3.11.6.3. Channel Strategy

20. Assumptions and Acronyms Used

21. Research Methodology